{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:37:02Z","timestamp":1784601422863,"version":"3.55.0"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T00:00:00Z","timestamp":1453680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"None reported"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>RSV causes considerable morbidity and mortality in children. In cystic fibrosis (CF) viral infections are associated with worsening respiratory symptoms and bacterial colonization. Palivizumab is effective in reducing RSV hospitalization in high risk patient groups. Evidence regarding its effectiveness and safety in CF is inconclusive. CF screening in N. Ireland enabled timely palivizumab prophylaxis, becoming routine in 2002.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To determine the effect of palivizumab on RSV\u2010related hospitalization and compare lung function and bacterial colonization at age 6 years for those born pre\u2010 and post\u2010introduction of palivizumab prophylaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective audit was conducted for all patients diagnosed with CF during the period from 1997 to 2007 inclusive. RSV\u2010related hospitalization, time to <jats:italic>Pseudomonas<\/jats:italic> aeruginosa (PA) 1st isolate, lung function and growth parameters were recorded. Comparisons were made for outcomes pre\u2010 and post\u2010introduction of routine palivizumab administration in 2002. A cost evaluation was also performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ninety\u2010two children were included; 47 pre\u2010 and 45 post\u2010palivizumab introduction. The overall RSV\u2010positive hospitalization rate was 13%. The relative risk of RSV infection in palivizumab non\u2010recipients versus recipients was 4.78 (95%CI: 1.1\u201320.7), <jats:italic>P<\/jats:italic>\u2009=\u20090.027. Notably, PA 1st isolate was significantly earlier in the palivizumab recipient cohort versus non\u2010recipient cohort (median 57 vs. 96 months, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.025) with a relative risk of 2.5. Chronic PA infection at 6 years remained low in both groups, with similar lung function and growth parameters. Total costs were calculated at \u00a396,127 ($151,880) for the non\u2010recipient cohort versus \u00a3137,954 ($217,967) for the recipient cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Palivizumab was effective in reducing RSV\u2010related hospitalization infection in CF patients. Surprisingly, we found a significantly earlier time to 1st isolate of PA in palivizumab recipients which we could not explain by altered or improved diagnostic tests. <jats:bold>Pediatr Pulmonol. 2016;51:379\u2013385<\/jats:bold>. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ppul.23376","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T16:38:56Z","timestamp":1453739936000},"page":"379-385","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and long\u2010term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland"],"prefix":"10.1002","volume":"51","author":[{"given":"H.E.","family":"Groves","sequence":"first","affiliation":[{"name":"Department of Paediatrics Royal Belfast Hospital for Sick Children Belfast United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Department of Cystic Fibrosis Royal Belfast Hospital for Sick Children Belfast United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Macfarlane","sequence":"additional","affiliation":[{"name":"Department of Cystic Fibrosis Royal Belfast Hospital for Sick Children Belfast United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Cystic Fibrosis Royal Belfast Hospital for Sick Children Belfast United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lynn","sequence":"additional","affiliation":[{"name":"School of Nursing and Midwifery Queen's University Belfast Belfast United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Paediatrics Queens University of Belfast Belfast United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,1,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268806006601"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1017\/S095026880200729X"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000126273.27123.33"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2003.036129"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.01.006"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2008.139188"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.11.1115"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1981.tb05757.x"},{"key":"e_1_2_6_10_1","first-page":"35","article-title":"Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis","volume":"137","author":"Zheng S","year":"2003","journal-title":"Immunity"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.1999.tb01230.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181673c15"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20751"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0022-3476(03)00454-2"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2006.0105338"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20922"},{"key":"e_1_2_6_18_1","first-page":"A189","article-title":"A phase IV study of the safety of SynagisTm (Palivizumab) for prophylaxis of respiratory syncytial virus","volume":"2","author":"Cohen AH","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22711"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aller.2013.09.003"},{"key":"e_1_2_6_21_1","volume-title":"NHS Reference Costs 2013\u20132014","year":"2014"},{"key":"e_1_2_6_22_1","volume-title":"British National Formulary","year":"2014"},{"key":"e_1_2_6_23_1","volume-title":"Unit Costs of Health and Social Care 2014","author":"Curtis L","year":"2014"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40248-015-0029-9"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.082768"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22946"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70116-8"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-0496(199812)26:6<371::AID-PPUL1>3.0.CO;2-N"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(88)80008-8"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.04.003"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.83.2.122"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88326-5"}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fppul.23376","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fppul.23376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.23376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T15:20:30Z","timestamp":1696519230000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.23376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,25]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1002\/ppul.23376"],"URL":"https:\/\/doi.org\/10.1002\/ppul.23376","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"value":"8755-6863","type":"print"},{"value":"1099-0496","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,25]]}}}